(NASDAQ: SYRE) Spyre Therapeutics's forecast annual revenue growth rate of 4.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Spyre Therapeutics's revenue in 2024 is $886,000.On average, 1 Wall Street analysts forecast SYRE's revenue for 2024 to be $36,150,941, with the lowest SYRE revenue forecast at $36,150,941, and the highest SYRE revenue forecast at $36,150,941. On average, 1 Wall Street analysts forecast SYRE's revenue for 2025 to be $36,150,941, with the lowest SYRE revenue forecast at $36,150,941, and the highest SYRE revenue forecast at $36,150,941.
In 2026, SYRE is forecast to generate $36,150,941 in revenue, with the lowest revenue forecast at $36,150,941 and the highest revenue forecast at $36,150,941.